UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 23, 2016
Anavex Life Sciences Corp.
(Exact name of registrant as specified in its charter)
| Nevada | 000-51652 | 98-0608404 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
51 West 52nd Street, 7th Floor, New York, NY USA 10019
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code1-844-689-3939
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
| Item 7.01. | Regulation FD Disclosure. |
On June 23, 2016, Anavex Life Sciences Corp., a Nevada corporation (the “Company”) delivered a presentation entitled “ANAVEX 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology” (“Presentation”) at the 2016 Rett Syndrome Symposium. The Presentation is attached hereto asExhibit 99.1 to this Current Report on Form 8-K.
In connection with the Presentation, the Company issued a press release announcing its participation in the Rett Syndrome Symposium (the “Press Release”). A complete copy of the Press Release is attached hereto asExhibit 99.2.
The information in thisItem 7.01 of the Current Report, includingExhibit 99.1 andExhibit 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item7.01 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
EXHIBIT NO. | | DESCRIPTION | | LOCATION | |
| | | | | | |
| Exhibit 99.1 | | Presentation:ANAVEX 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology | | | Provided herewith | |
| | | | | | | |
| Exhibit 99.2 | | Press Release dated June 23, 2016 RegardingPresentation at Rett Syndrome Symposium | | | Provided herewith | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ANAVEX LIFE SCIENCES CORP. |
| | |
| | /s/ Christopher Missling, PhD |
| | Name: Christopher Missling, PhD |
| | Title: Chief Executive Officer |
Date: June 23, 2016
